BioNexus Gene Lab Corp Common stock Cash Flow Conversion Efficiency
BioNexus Gene Lab Corp Common stock cash flow conversion efficiency. Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has a cash flow conversion efficiency ratio of -0.181x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.23 Million) by net assets ($6.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioNexus Gene Lab Corp Common stock (2016–2024)
Cash flow conversion efficiency of BioNexus Gene Lab Corp Common stock from 2016 to 2024. This chart illustrates how BioNexus Gene Lab Corp Common stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BGLC stock price for real-time trading data and today's change.
BioNexus Gene Lab Corp Common stock Cash Flow Conversion Ratio Explained
BioNexus Gene Lab Corp Common stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioNexus Gene Lab Corp Common stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their cash flow conversion efficiency. Also see BioNexus Gene Lab Corp Common stock (BGLC) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
-0.282x |
|
The Income & Growth VCT
LSE:IGV
|
-0.016x |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
0.025x |
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
0.008x |
|
Invion Ltd
AU:IVX
|
-0.163x |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
-0.002x |
|
Majedie Investments
LSE:MAJE
|
0.008x |
|
Catheter Precision Inc.
NYSE MKT:VTAK
|
-0.227x |
Annual Cash Flow Conversion Efficiency for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of BioNexus Gene Lab Corp Common stock from 2016 to 2024. Review BGLC cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $8.32 Million | $-2.23 Million | -0.268x | -47.24% |
| 2023-12-31 | $9.66 Million | $-1.76 Million | -0.182x | -323.36% |
| 2022-12-31 | $6.67 Million | $544.03K | 0.082x | +6297.18% |
| 2021-12-31 | $7.18 Million | $9.16K | 0.001x | -98.46% |
| 2020-12-31 | $6.66 Million | $552.68K | 0.083x | +142.85% |
| 2019-12-31 | $1.12 Million | $-217.27K | -0.194x | -7.49% |
| 2018-12-31 | $1.52 Million | $-274.08K | -0.180x | -104.77% |
| 2017-12-31 | $94.63K | $357.22K | 3.775x | +492.70% |
| 2016-12-31 | $-1.31K | $-835.00 | 0.637x | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more